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Identification of podocin (NPHS2) gene mutations in African
Americans with nondiabetic end-stage renal disease.
Background. Podocin, encoded by NPHS2 and mapped to
1q25.2, is an integral membrane protein exclusively expressed
in glomerular podocytes. Mutations in the NPHS2 gene cause
autosomal-recessive nephrotic syndrome and have been associ-
ated with proteinuria in several populations. Evidence for link-
age of end-stage renal disease (ESRD) to chromosome 1q25-31
in the region of NPHS2 has been identified in a genome-wide
scan in African American (AA) siblings.
Methods. To investigate the potential role of this gene in
ESRD, we sequenced all coding regions and approximately 2 kb
of upstream promoter sequence of NPHS2 in 96 unrelated AA
nondiabetic ESRD cases and 96 healthy population-based AA
controls, and assessed several single nucleotide polymorphisms
(SNPs) for association in a larger case-control sample.
Results. Fifty-five variants were identified with minor allele
frequencies ranging from <1% to 44%. Twenty-three polymor-
phisms were located in the promoter region, 11 were exonic,
13 were intronic, and 8 were in the 5′ and 3′- untranslated
regions. Two novel nonsynonymous coding SNPs were iden-
tified (A44E and A61V). An insertion polymorphism in intron
3, IVS3+9insA, was detected in 6 ESRD patients and in no
controls. This variant, and 4 other common SNPs, were evalu-
ated in a larger sample of 288 AA ESRD cases and 278 AA
controls. The overall minor allele frequencies for the insertion
allele were 0.018 in cases and 0.002 in controls. Significant evi-
dence of association of IVS3+9insA was observed (P = 0.012),
and the haplotype containing the insertion allele in cases was
also associated.
Conclusion. These results suggest that uncommon variants
of the NPHS2 gene may play a role in the development of non-
diabetic ESRD in AAs.
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End-stage renal disease (ESRD), with its associated
glomerulosclerosis and interstitial fibrosis, is a major
cause of morbidity and mortality worldwide. The lead-
ing causes of ESRD are diabetic nephropathy, hy-
pertension, and chronic glomerular diseases. Alarming
increases in health care costs and numbers of individu-
als affected by ESRD have recently been reported. More
than 96,000 Americans were diagnosed with ESRD, and
364,000 received renal replacement therapy (dialysis) in
2001 (www.usrds.org). These numbers are expected to
double within the next decade. While ESRD is clearly a
multifactorial disease, several lines of evidence support a
genetic contribution to its pathogenesis [1–4].
The glomerular capillaries can become injured in a va-
riety of systemic and renal-limited diseases [5]. Podocytes,
visceral epithelial cells, are octopus-like cells containing
actin-rich foot processes that sit on the external surface
of the glomerular basement membrane (GBM). Each
podocyte is attached to its neighboring cell by an inter-
cellular adherens-type junction termed the slit diaphragm
(SD) [6], bridging the narrow spaces (30-40 nm) between
cells. The GBM is both a size- and charge-selective bar-
rier for plasma proteins, and the SD maintains the bar-
rier toward plasma macromolecules. Many proteinuric
glomerular diseases are associated with effacement of the
podocyte foot processes, enhancing leakage of proteins
across the SD into the urine.
Podocin (NPHS2) is a stomatin-like protein that is
exclusively expressed in podocytes. It is a membrane-
anchored protein that interacts with other key compo-
nents such as nephrin, CD2-associated protein, and Kin
of Irre-like (KIRREL, NEPH1) at the SD [7–12]. It
has been suggested that podocin works as a scaffold-
ing protein in the SD assembly process, but its precise
function has not been fully elucidated. Podocin knock-
out mice (NPHS2−/−) develop proteinuria during the
antenatal period and die from renal failure shortly af-
ter birth [7]. Mutations in NPHS2 have been associated
with autosomal-recessive steroid-resistant nephrotic syn-
drome in children and families [13–15], sporadic focal
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segmental glomerular sclerosis [16–18], proteinuria after
renal transplantation [19], and with microalbuminuria in
the general population [20].
In light of the role of podocin in the glomerular filtra-
tion barrier and the association of genetic variants of the
NPHS2 gene with several renal disorders, this gene is a
functional candidate gene for ESRD. Our prior genome-
wide scan of nondiabetic ESRD in AA sibling pairs re-
vealed suggestive evidence for linkage at the NPHS2 gene
locus on chromosome 1q25-31 [21]. Hence, podocin is
also a positional candidate gene for ESRD in AAs. We
investigated the role of the NPHS2 gene in AA non-
diabetic ESRD in a case-control study. We directly se-
quenced the gene in affected and unaffected individuals
in order to identify genetic variants contributing to non-
diabetic ESRD.
METHODS
Participants
We recruited 288 unrelated AAs born in North
Carolina reportedly with hypertension-associated ESRD
from dialysis facilities located in the northwestern region
of the state. These individuals were all nondiabetic and
had hypertension listed as the etiology of ESRD on their
CMS 2728 form. In addition, 278 reportedly healthy (non-
renal diseased) AAs also born in North Carolina were
recruited as population-based controls. This study was
approved by the Institutional Review Board at the Wake
Forest University School of Medicine, and all cases and
controls provided written informed consent [22].
Sequencing of the podocin gene
All 8 exons, including the 3′ and 5′ untranslated regions,
and 2.2 kb of upstream promoter sequence, were directly
sequenced in 96 AA ESRD cases and 96 healthy AA
population-based controls. The sequence of primers used
for PCR amplification of target sequences is available on
request. Fragments were amplified in 20-lL reaction vol-
umes using standard polymerase chain reaction (PCR)
techniques, and the products were purifed with filter
plates (Eppendorf) according to manufacturer’s proto-
cols. Cleaned PCR products were then directly sequenced
using Big Dye Ready Reaction Mix (Applied Biosystems,
Foster City, CA, USA), and the sequence determined
on an ABI 3730xl (Applied Biosystems). All sequences
were compared with reference sequence NT 004487, and
with each other, for the detection of variations using
Sequencher software (GeneCodes, Ann Arbor, MI,
USA).
Genotyping
Five SNPs were chosen for further analysis in the
larger sample: IVS+9insA, C725T, T954C, C1206G, and
A1410G. These were genotyped in an additional 192 cases
and 182 controls using a MassARRAY SNP genotyp-
ing system (Sequenom, Inc., San Diego, CA, USA) as
previously described [22]. This genotyping system uses
single base extension reactions to create allele specific
products that are separated and automatically scored in a
MALDI-TOF mass spectrometer. Primers for PCR am-
plification and extension reactions were designed using
MassARRAY assay design software (Sequenom, Inc.)
and are available on request.
Statistical analysis
Clinical characteristics were compared between the re-
sequenced sample and the remainder of ESRD affected
participants using Student t test for comparison of means
and a chi-square test for comparison of proportions. SNPs
were tested for Hardy-Weinberg Equilibrium (HWE) us-
ing the normal 2 × 3 chi-squared 1 degree of freedom (df)
test of goodness-of-fit to HW proportions. The pairwise
linkage disequilibrium statistic (D′) was calculated using
Haploview software with the solid spine of LD algorithm
with a threshold of D′ = 0.7 [23]. Pearson chi-square test
was used to assess allele and genotype frequency distribu-
tion differences between individuals affected by ESRD
and unaffected controls. If any cell contained fewer than
5 counts, Fisher exact test was employed. Genotypic as-
sociation was also assessed under a priori genetic mod-
els (dominant and recessive). Haplotypes were estimated
and assessed for association using DANDELION, which
implements an expectation-maximization algorithm [24].
The empirical P value was calculated from 10,000 permu-
tations. P values < 0.05 were considered significant in all
analyses.
RESULTS
We evaluated a total of 288 AA nondiabetic ESRD
cases and 278 AA population-based controls. Clinical
characteristics of the study group are shown in Table 1.
There was a slight excess of males in the overall study,
as is also present in the United States Renal Data Sys-
tem (USRDS) database. The mean ± SD age at ESRD
onset was 48.1 ± 15.7 years, with a mean duration of hy-
pertension before ESRD of 14.0 ± 13.3 years. The rese-
quenced subset was slightly younger than the remainder
of the sample (P = 0.04), and the mean age at ESRD
onset in the resequenced subset was also lower than the
remainder of the sample, although this did not reach sta-
tistical significance (P = 0.07). The mean body mass index
(BMI) did not differ between the resequenced subsample
and the remainder of the sample, nor did the presence of
hypertension, its mean age at onset, or the duration of
hypertension prior to ESRD onset.
Sequencing of 96 ESRD cases and 96 population con-
trols revealed 55 variable locations within the coding
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Table 1. Clinical characteristics of the patient sample (mean ± standard deviation) and comparison of the resequenced subset to the remainder
of the samplea
Total Resequenced Nonresequenced P value
sample (288) sample (96) sample (192) for difference
Female% N 43.4% (125) 44.8% (43) 42.7% (82) 0.73
Age 54.7 ± 14.9 52.1 ± 15.0 56.0 ± 14.7 0.04
Age at onset of ESRD 48.1 ± 15.7 45.8 ± 14.9 49.3 ± 15.9 0.07
Hypertension% N 99.7% (287) 100% (96) 99.5% (191) 0.91
Age at onset of hypertension 32.9 ± 12.5 32.5 ± 11.3 33.2 ± 13.2 0.64
Duration hypertension pre-ESRD 14.0 ± 13.3 13.1 ± 12.3 14.6 ± 14.0 0.39
BMI at study entry kg/m2 26.5 ± 7.2 26.6 ± 7.8 26.5 ± 7.0 0.88
aData expressed as mean ± standard deviation, age, and duration expressed in years.
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Fig. 1. Schematic of NPHS2 gene with all SNPs identified, 5′ to 3′. Solid boxes are translated exons, open boxes are untranslated. Intronic SNPs
are named with positive numbers counting from the end of the preceding exon, or negative numbers counting from the start of the following exon.
SNPs with minor allele frequency >10% in controls are bold. Those in protein coding regions are italic. Not to scale.
regions, including all exons and flanking regions and
2.2 kb of upstream promoter sequence (Fig. 1). Vari-
ants are named as recommended by Antonarakis et al
[25]. Up to 6.5 kb of sequence was generated from each
sample. All variants in the promoter and mRNA were
numbered with respect to the start of translation. Five
variants were insertion/deletion polymorphisms and the
remaining 50 variants were SNPs. Twenty-three variants
were in the promoter region and eight were in untrans-
lated exons. Eleven were in translated regions and six
of these were nonsynonomous, giving rise to amino acid
changes in the protein. Sixteen variants had a minor allele
frequency (MAF) > 10% in controls, and an additional
10 SNPs had a frequency of between 5% and 10% in
controls (Table 2). Two of these, A44E and A61V, had
not been previously reported and had MAF of 0.005 and
0.016, respectively. Thirteen variants were detected in in-
tronic regions, although introns were not fully sequenced.
All SNPs were found to be consistent with HW expecta-
tions. Linkage disequilibrium between SNPs with MAF >
0.1 was assessed in controls and revealed several blocks
of high linkage disequilibrium (D′ > 0.7), although the
values in block 1 did not reach statistical significance
(Fig. 2).
NPHS2 mutations have previously been implicated in
renal disease in an autosomal-recessive manner, requir-
ing two defective alleles for the presentation of disease
[14, 26]. We observed no cases in which rare coding mu-
tations identified in this study (P20L, A44E, R229Q, or
E237Q) were homozygous. These alleles were observed
in both cases and controls, and only in the heterozy-
gous state. Also, no compound heterozygotes for mul-
tiple nonsynonomous coding mutations were observed.
The novel variant, A61V, although rare, was observed to
be homozygous in two affected individuals. The actual
allele frequencies were similar between cases and con-
trols, but the homozygous genotype may have had some
effect, although it is difficult to draw conclusions from the
small numbers observed. Interestingly, one of these ho-
mozygous ESRD patients was also homozygous for five
rare variants in the promoter region (G-1441A, G-1376A,
G-1112A, A-1087C, and C-770T), and was the only ob-
served carrier for three of these SNPs. Karyotyping and
fluorescent in situ hybridization (FISH) analysis of this
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Table 2. Genetic variants of NPHS2 identified in cases and controls with minor allele frequencies and P values for allelic association with
hypertension-associated ESRD in 96 cases and 96 controls
Allele frequencies
Name Location in gene Cases Controls P value Coding change dbSNP identifier Reference
A-2169T Promoter 0.010 0.021 0.448
C-1842G Promoter 0.026 0.026 1.000
G-1709A Promoter 0.066 0.108 0.286
-1707delCT Promoter 0.000 0.010 0.247
G-1628C Promoter 0.072 0.069 0.919
G-1441A Promoter 0.021 0.010 0.694
G-1376A Promoter 0.021 0.010 0.694
T-1363C Promoter 0.005 0.000 0.919
-1147delATCT Promoter 0.038 0.021 0.356
G-1112A Promoter 0.010 0.000 0.451
A-1087C Promoter 0.010 0.000 0.451
T-999A Promoter 0.122 0.148 0.481 rs2026014
C-770T Promoter 0.010 0.000 0.451
C-748T Promoter 0.061 0.088 0.355
G-704A Promoter 0.034 0.019 0.509
C-670T Promoter 0.236 0.236 1.000 rs3829795
-556delCTTTTTT Promoter 0.118 0.135 0.632
G-494A Promoter 0.042 0.019 0.322
-486insA Promoter 0.143 0.156 0.746
T-440C Promoter 0.038 0.019 0.437
C-364T Promoter 0.005 0.021 0.214
T-185C Promoter 0.118 0.085 0.320
C-116T Promoter 0.078 0.109 0.336 rs4271172
C-52G Exon 1 5′UTR 0.182 0.168 0.748
G-51T Exon 1 5′UTR 0.156 0.179 0.565 rs12406197
C59T Exon 1 0.005 0.005 1.000 P20L [8]
G102A Exon 1 0.154 0.150 0.926 G34G rs3818588 [13]
C176A Exon 1 0.005 0.005 1.000 A44E
C182T Exon 1 0.026 0.016 0.477 A61V
C289T Exon 2 0.098 0.098 0.997 S96S rs3738423 [13]
IVS3+9insA Intron 3 0.032 0.000 0.015
IVS3-144C>T Intron 3 0.037 0.033 0.808
IVS3-46C>T Intron 3 0.080 0.060 0.449 rs12401711
IVS3-32T>G Intron 3 0.010 0.000 0.499
IVS3-31T>C Intron 3 0.144 0.136 0.829
IVS3-21C>T Intron 3 0.080 0.060 0.449 rs12401708
IVS4-98C>T Intron 4 0.027 0.021 0.750
G686A Exon 5 0.000 0.005 0.317 R229Q [13, 28]
G709C Exon 5 0.005 0.000 0.319 E237Q [26]
C725T Exon 5 0.032 0.074 0.070 A242V [26]
IVS5+110T>A Intron 5 0.223 0.163 0.138
IVS7+7A>G Intron 7 0.010 0.010 1.000 [29]
IVS7+132A>G Intron 7 0.010 0.016 0.652
IVS7+261C>T Intron 7 0.005 0.010 0.562
IVS7+304T>C Intron 7 0.010 0.010 1.000 rs11808359
IVS7-74G>C Intron 7 0.091 0.095 0.911 rs2274624
G891A Exon 8 0.027 0.016 0.456 A297A rs5005771
T954C Exon 8 0.441 0.400 0.422 A318A rs1410592 [13, 30]
A1038G Exon 8 0.102 0.095 0.809 L346L rs3818587 [13, 30]
C1206G Exon 8 3′UTR 0.446 0.400 0.364 rs1410591
A1309G Exon 8 3′UTR 0.124 0.116 0.814 rs1410590
G1352A Exon 8 3′UTR 0.027 0.058 0.136 rs2274623
A1410G Exon 8 3′UTR 0.139 0.200 0.132 rs2274622
G1580A Exon 8 3′UTR 0.144 0.144 0.985 rs1060775
G1589T Exon 8 3′UTR 0.017 0.013 0.751
individual revealed normal chromosomes and no de-
tectable microdeletion of the region, indicating true ho-
mozygosity of a rare haplotype (data not shown). The
second individual homozygous for A61V did not carry
any of these other variants, indicating that this allele was
present on at least two haplotypes.
These results did not reveal homozygous or compound
heterozygous mutations of NPHS2 as a significant con-
tributor to hypertension-associated ESRD. Association
analysis of all detected variants was performed with data
from the 96 cases and 96 controls to identify differences
between allele frequencies in case and control groups
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Fig. 2. Haploview output for pairwise D′ values in controls for SNPs with MAF >10%. Empty cells indicate D′ = 1.0 = 100%. Gray cells indicate
a lack of statistical significance. Inset shows the SNPs genotyped in the total sample excluding IVS3+9insA due to its rarity in the control sample.
that may contribute to the risk of ESRD and indicate
which SNPs should be assessed in a larger sample. Geno-
type frequencies were consistent with HW proportions
for all SNPs. Allele frequencies of each SNP and P val-
ues for allelic association are shown in Table 2. The ma-
jority of variants showed no evidence of association with
ESRD in this AA population. However, the intronic SNP
IVS3+9insA was significantly associated with ESRD
(P value = 0.015). C725T, a nonsynonomous SNP result-
ing in a conservative amino acid substitution of valine
for alanine at codon 242, showed borderline significance
(P = 0.070). These two variants were chosen for addi-
tional investigation in the entire sample. Although not
reaching significance in the preliminary analysis, T954C,
C1206G, and A1410G were also included in follow-up.
These three variants are all present in coding regions
and, therefore, are perhaps more likely to be functional
than some intronic SNPs. They are also relatively com-
mon in this population and would fit with the “common
disease common gene” hypothesis for complex common
diseases, such as ESRD. The larger sample would provide
increased power to detect small differences in allele fre-
quencies that may not have been evident in the subsample
of individuals sequenced.
These five SNPs (Table 3) extend from intron 3 to the
3′UTR (a distance of 10.7 kb), and are in a single block of
linkage disequilibrium (Fig. 2, inset). In the larger dataset,
it appeared that blocks 1 and 2 from the initial analysis
were actually one single block. Allelic association anal-
ysis of these five SNPs in 288 cases and 278 controls re-
vealed significant association of the IVS3+9insA variant
with nondiabetic ESRD (P = 0.012) (Table 3). This SNP
was observed in the heterozygous state in 10 cases and
in only one control (allele frequencies of 0.018 and 0.002,
respectively). No carriers of this allele carried additional
nonsynonomous mutations. The C725T SNP remained
of borderline significance (P = 0.080), and the three re-
maining SNPs were not significantly associated (P > 0.1)
(Table 3). The genotypes of these five SNPs were
also not associated with ESRD, with the exception of
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Table 3. P values for allelic and genotypic association of five SNPs in the NPHS2 gene with ESRD
Allele frequencies P values for genotypic association
Allelic
SNP Coding change Cases Controls P value Overall Dominanta Recessiveb
IVS3 + 9insA 0.018 0.002 0.012 0.012 0.018 N/A
C725T A242V 0.060 0.087 0.080 0.105 0.139 0.356
T954C A318A 0.433 0.404 0.335 0.288 0.421 0.298
C1206G 0.436 0.413 0.430 0.324 0.457 0.327
A1410G 0.111 0.133 0.287 0.394 0.234 1.000
N/A, the recessive model could not be assessed due to 0 observed carriers of the 2/2 genotype.
aThe dominant model tests the pooled 1/2 and 2/2 genotypes vs. 1/1.
bThe recessive model tests the 2/2 genotype vs. the pooled 1/1 and 1/2 genotypes.
Table 4. Haplotypes observed in cases and controls and P values for
association with ESRD
Frequency Overall
Haplotype empirical
Haplotypea Cases Controls P value P value
1 C C G A 0.433 0.403 0.482
1 C T C A 0.394 0.376 0.663
1 C T C G 0.094 0.123 0.273
1 T T C A 0.060 0.084 0.259
1 C C G G 0.000 0.006 0.180 0.0012
1 T T C G 0.000 0.003 0.366
1 C T G A 0.002 0.002 0.961
2 C T C A 0.000 0.002 0.456
2 C T C G 0.018 0.000 0.027
aSNPs in order are IVS3+9insA, C725T, T954C, C1206G, A1410G.
IVS3+9insA under a dominant model (Table 3). The re-
cessive model could not be calculated for this SNP due to
a complete lack of the 2/2 genotype in this sample.
Haplotype analysis of the 5 SNPs provided additional
support for the contribution of IVS3+9insA. An overall
empirical P value for haplotypic association of 0.0012 was
observed. A rare haplotype containing the insertion allele
for IVS3+9insA was present only in cases and showed as-
sociation with ESRD with a haplotype specific P value of
0.027 (Table 4). None of the other haplotypes demon-
strated significant association. The single unaffected con-
trol carrier of IVS3+9insA appears to carry this variant
on a different haplotype than the affected individuals, de-
fined by the A1410G SNP; however, the rarity of these
haplotypes indicates that results should be interpreted
with caution.
DISCUSSION
This is the first analysis of the podocin (NPHS2) gene
in nondiabetic ESRD in AAs. This gene was chosen as a
positional candidate gene, as it resides within the chromo-
some 1q25-31 linkage peak that we observed in a genome
scan for nondiabetic ESRD in AA families. The results
of this analysis indicate that rare variants of the NPHS2
gene may contribute to nondiabetic ESRD in AAs,
particularly the IVS3+9insA mutation. Although this
variant was observed in one population-based control
subject, it should be remembered that ESRD is a late
onset disease. Although controls were chosen from the
same age group as cases, it is possible that this control
subject will develop ESRD in the future. ESRD is also a
complex disease with many contributing genetic and envi-
ronmental factors, and the IVS3+9insA mutation is likely
not fully penetrant. Only 11 insA alleles were detected in
this study of 1132 chromosomes. The rarity of this vari-
ant increases the likelihood of false-positive results. This
variant should be screened in other AA ESRD and con-
trol samples in order to determine its overall relevance
to ESRD. The frequency of this variant in other ethnic
groups, and in other etiologies of ESRD (e.g., diabetes-
associated ESRD), will need to be determined.
The mechanism by which this intronic mutation could
contribute to renal disease is not known. However, the
insertion is close to the exon 3/intron 3 boundary, and
may disrupt the splice site, resulting in aberrant mRNA.
While this splice site contains the invariant GT as the
first two bases, it is not a traditional consensus splice sig-
nal (e.g., GT A/G AGT) [27], but instead contains a se-
ries of adenines (GTAAAAAACAC), with the mutation
introducing an additional A. As NPHS2 is expressed ex-
clusively in glomerular podocytes, it is difficult to assess
the effects of the mutation on mRNA splicing in affected
cells.
Several previous investigations of this gene have fo-
cused on both familial and sporadic steroid resistant
nephrotic syndrome (SRNS). While NPHS2 is not re-
sponsible for all cases of this predominantly autosomal-
recessive disorder, the presence of two functional
mutations (homozygosity or compound heterozygosity)
of the NPHS2 gene results in SRNS [13–15]. The signif-
icance of familial cases with only one heterozygous mu-
tation is unclear. There may be additional mutations in
regulatory regions that account for disease [14], or an
NPHS2 mutation may interact with other genes to con-
tribute to disease only in certain genetic environments.
In a similar fashion, NPHS2 may contribute to ESRD.
The R229Q polymorphism is not thought to cause dis-
ease when present alone as a heterozygous variant [28].
However, it has been shown that in combination with an-
other heterozygous mutation (in this case, R291W), it
262 Engeler and Burdon et al: Podocin gene in ESRD
contributes to autosomal-recessive focal segmental
glomerulosclerosis [28]. In addition, it has been associ-
ated with microalbuminuria in the general population
[20]. While this particular variant was not common in the
AA sample studied here (consistent with other studies
[20, 28]), the other coding variants may contribute to dis-
ease in certain genetic or environmental circumstances.
However, the rarity of these variants makes this difficult
to test.
CONCLUSION
We report the identification of several novel variants
of the NPHS2 gene in AAs, including two coding vari-
ants (A61V and A44E). While this gene was not a major
contributor to nondiabetic ESRD, uncommon variants, in
particular, IVS3+9insA, may contribute to a proportion
of this disease in the African American population.
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